Likewise, current pre-clinical models demonstrate that TIM-3 blockade can result in reduced glioblastoma growth and enhanced survival in vivo and combination therapies including TIM-3 inhibitors show greater promise than monotherapies. Here, HAVCR2 is linked to glioblastoma.